Navigation Links
Interleukin-12 indicates survival prospects for melanoma patients

SAN DIEGO - Higher blood levels of an immune system protein predict poor survival prospects for melanoma patients with advanced disease, researchers at The University of Texas M. D. Anderson Cancer Center report today at the annual meeting of the American Association for Cancer Research.

Their finding that elevated levels of interleukin-12 (IL-12) are a marker of poor prognosis also points to a molecular explanation for a long-known risk factor for melanoma patients - older age.

Among 150 patients with Stage III melanoma, the study found that the highest levels of IL-12 are associated with a nearly 5-fold risk of death. Although older stage III patients also had an elevated risk of death, age was not a prognostic factor independent of IL-12.

"Melanoma in some cases can be vulnerable to attack by a patient's immune system," said senior researcher Jeffrey Lee, M. D., professor in M. D. Anderson's Department of Surgical Oncology. "What we've found could be evidence of a dysfunctional immune response that actually fuels the growth of melanoma."

Blood-born IL-12 provides both an accessible prognostic marker and a key connection to other signaling proteins; IL-12 as well as these related proteins already have been targeted by antibody therapies in certain autoimmune disorders, Lee said.

The research team examined age, stage of disease, and IL-12 levels in 658 melanoma patients - 445 with stage I or II disease, 150 with stage 3 and 63 at stage IV.

"First, we found that IL-12 levels increase with age," says first author and study presenter Yun Shin Chun, M.D. The mean levels of the protein increased at every age level above age 40. (See Chart)

Age, disease stage and IL-12 levels were then analyzed separately as prognostic factors. Increases in all three were associated with poor overall survival.

"When we analyzed these three factors together, only stage of disease and IL-12 levels were independent predictors of overall survival," Chun said. Age dropped completely out of the picture. Stage of disease was the most powerful prognostic factor.

Both IL-12 and IL-23 are cytokines, proteins that tell cells and other proteins what to do. Cytokines like IL-12 and IL-23 are particularly vital to immune system function. The general level of a person's immune function declines with age, Lee said, as do the levels of most cytokines. The rise of IL-12p40 with age is a relative anomaly.

Chun, Lee and colleagues are investigating IL-12's connection to the tumor promoting IL-23 and about 30 other cytokines in high-risk melanoma patients. Some of the suspect cytokines, including IL-12 and IL-23, already are targeted by therapies used autoimmune disease, Lee noted.

Age Mean level of

< 40
80 >


Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. MSU research indicates testosterone could guard against eating disorders
2. New research indicates that a common heart drug
3. Surprising New Research Indicates that Significant Numbers of Children as Young as 11 are Engaging in Sexual Activity and that Dating Violence and Abuse are Part of Their Relationships
4. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
5. U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
6. New Study Indicates Decreasing Prescription Copayments Results in Increased Adherence for Patients with Chronic Diseases
7. Study Indicates Strong Consumer Preference to Fix Medicare Part D and Medicaid Flaws Threatening Access to Prescription Drugs
8. Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
9. Research Indicates Nearly 25 Percent of Supplements Are Contaminated With Steroids, Stimulants and Banned Substances
10. Study indicates pregnancy does not harm chances of survival from cancer
11. Mayo Clinic study indicates medication for ADHD may help student outcomes
Post Your Comments:
Related Image:
Interleukin-12 indicates survival prospects for melanoma patients
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: